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Nutritional support has become a routine part of the care of the critically ill
patient. It is an adjunctive therapy, the main goal of which is to attenuate the
development of malnutrition, yet the effectiveness of nutritional support is often
thwarted by an underlying hostile metabolic milieu. This requires that these
metabolic changes be taken into consideration when designing nutritional
regimens for such patients. There is also a need to conduct large, multi-center
studies to acquire more knowledge of the cost–benefit and cost effectiveness of
nutritional support in the critically ill.
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Introduction
Nutritional support has become a routine part of the care of the
critically ill patient. It is an adjunctive therapy, the main goal of
which is to attenuate the development of malnutrition. The
effectiveness of nutritional support is often stymied by an under-
lying hostile metabolic milieu. The design of a nutritional support
regimen must, therefore, take into consideration this disordered
metabolic situation.
The metabolic milieu
Acute stress caused by accidental or surgical injury, sepsis,
burns or other serious illnesses, such as myocardial infarc-
tion, results in the outpouring of counter-regulatory
endocrine hormones, cytokines and lymphokines. This
results in changes in substrate utilization and substance
synthesis rates, as well as catabolism and hypermetabolism.
Consequently, there is loss of fat and lean body (muscle)
mass, a problematic situation that has been dubbed ‘auto-
cannibalism’. Thus, it is not surprising that this abnormal
metabolic milieu causes disordered utilization of exoge-
nously administered nutrients. Conventional nutritional
strategies, such as providing the equivalents of a usual
human diet, frequently do not prevent or attenuate the
loss of muscle and fat tissue. As a result, many investiga-
tional efforts have been directed at overcoming or circum-
venting the obstacles placed by this disordered milieu.
Glucose metabolism
Pathophysiology
The metabolic response to stress is characterized by major
alterations in glucose metabolism. The increased secretion
of the counter-regulatory (to insulin) hormones cortisol, cat-
echolamines and glucagon [1] results in elevated endoge-
nous glucose production that is secondary to accelerated
hepatic gluconeogenesis (Fig. 1). This increased glucose
production ,coupled with peripheral tissue resistance to
insulin, results in reduced glucose utilization and causes
hyperglycaemia. Insulin levels are usually within the normal
or mildly elevated range, but are not sufficiently elevated to
prevent hyperglycaemia. Hyperglycaemia may also be due
to reduced nonoxidative glucose disposal that results from
decreased muscle glycogen synthetase activity [2,3]. The
hyperglycaemia is thought to ensure a ready supply of
glucose to predominantly glucose-consuming cells, such as
the wound, inflammatory cells and immune cells [4].
Insulin resistance in peripheral tissues is thought to be
due to a postreceptor defect, and is thought to hinder cel-
lular glucose uptake. This defect is possibly caused by
impaired activity of the intracellular glucose transport
system and does not appear to be due to impaired sig-
nalling of phosphatidylinositol 3-kinase [5]. Insulin resis-
tance occurred after both elective open and laparoscopic
ATP = adenosine triphosphate; TPN = total parenteral nutrition; TNF = tumour necrosis factor; IL = interleukin; LCT = long-chain triglycerides;
MCT = medium-chain triglycerides; IGF = insulin growth factor.cholecystectomy, and persisted for at least 5 days [6,7]. The
overall amount of glucose oxidized may be decreased,
despite a glucose oxidization pathway that is thought to be
intact, because of the reduced rate of glucose uptake into
the cell [3]. The incremental response to increases in insulin
concentration is maintained [8], but the ability to reduce
blood glucose concentrations per insulin concentration is
markedly diminished [9]. Despite the resistance to insulin,
the overall peripheral uptake of glucose is often ‘normal’ or
mildly elevated due to increased noninsulin-mediated
glucose uptake. Relative to the blood glucose concentration
the uptake is low, however [10]. Also, the ‘normal’ or mildly
elevated peripheral glucose uptake may be fueled by the
large amounts of glucose (due to hyperglycaemia) being pre-
sented to the partially resistant insulin pathway [1].
Glucose can be oxidized to produce adenosine triphos-
phate (ATP), water and carbon dioxide; converted to
glycogen for storage in the liver and muscles; or converted
to fat. The latter process is called lipogenesis and occurs in
both liver and adipose tissue, although the latter appears
to be the main site for lipogenesis [11]. Under normal cir-
cumstances carbohydrate intake inhibits fat oxidation,
increases glucose oxidation and promotes fat storage [12].
Lipogenesis is usually quantitatively unimportant in
humans because the rate of lipogenesis does not exceed
the rate of lipid oxidation [13]. When carbohydrate intake
exceeds total energy expenditure, however, lipogenesis
becomes a more important pathway [14], and respiratory
quotients may exceed 1.0, indicating net lipogenesis. This
may be seen among patients receiving glucose infusions of
>4mg/kg per min [15]. Critically ill patients administered
intravenous glucose at a rate of 4mg/kg per min as part of
glucose-based total parenteral nutrition (TPN) exhibited
some increased hepatic de-novo lipogenesis, despite
achieving an respiratory quotient of only 0.90 [16]. This
lipogenesis occurred despite the fact that during surgical
or septic stress lipogenetic capability is thought to be
reduced. This is possibly secondary to tumour necrosis
factor (TNF), which, among other factors, can induce
apoptosis of preadipocytes and adipocytes [17]. Inter-
leukin (IL)-1b also appears to inhibit lipogenesis in
human adipocytes [18].
Exogenous glucose and carbohydrate administration
The administration of exogenous glucose and carbohy-
drates to injured or septic patients either does not or only
minimally diminishes the rate of gluconeogenesis [16]. This
is in contradistinction to refeeding starved patients where
carbohydrate administration reduces gluconeogenesis and
lipolysis. Despite the reduced utilization of glucose, it is
still important to administer carbohydrates, because some
body tissues are unable to use other substrates readily. Fur-
thermore, glucose and carbohydrate intakes stimulate the
secretion of additional insulin, an anabolic hormone that
promotes protein synthesis [19] and has an antilipolytic
affect [20,21]. The appearance of hyperglycaemia limits the
amount of glucose and carbohydrate that can be adminis-
tered, however. The degree of TPN-induced hypergly-
caemia is directly proportional to the rate of glucose
infusion and the degree of injury. Elderly patients are more
predisposed to develop hyperglycaemia [22].
Excessive glucose loads (>4mg/kg per min), especially
when administered to acutely stressed patients receiving a
total caloric intake greater than resting energy expenditure,
results in a thermogenic response, further elevation of
blood glucose concentrations and production of additional
carbon dioxide [23]. If the patient is no longer stressed res-
piratory quotients may exceed 1.0, indicating net lipogene-
sis [24]. This additional carbon dioxide must be excreted
via the lungs. A recent survey of US teaching hospitals by
Schloerb et al [25] demonstrated that many were feeding
their patients more than 4.5mg/kg per min glucose, thus
increasing the possibility of glucose overload.
Critically ill patients often receive carbohydrates from a
variety of sources other than the glucose in TPN or carbo-
hydrates in enteral nutrition. They receive infusions of 5%
dextrose and the glycerol in lipid emulsions also enters the
gluconeogenic pathway. Glucose-containing solutions are
also used for peritoneal dialysis and continuous veno–veno
haemodialysis. The dialysate solution used during contin-
uous veno–veno haemodialysis often contains glucose
(usually 1.5%). A significant amount of the glucose
(35–45%) can be absorbed, and is thus a source of carbohy-
drate calories [26]. Similarly, glucose-containing solutions
used as replacement solution during haemofiltration can
be a source of glucose calories, in one study [27] providing
300g/day glucose.
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Figure 1
Hepatic gluconeogenesis is increased during stress. Sources of
substrate include glycerol from lipolysis, alanine from proteolysis and
lactate from anaerobic glycolysis.Alternate fuels
Nonglucose carbohydrates have been tried experimentally
in attempts to bypass the problems of decreased glucose
disposal. Sorbitol, fructose and xylitol have been tried, but
were found to be problematic [28]. Glycerol has been used
with some success, although the amount that can be
infused is limited [29].
Lipid metabolism
Pathophysiology
Various stresses, including injury, sepsis and congestive
heart failure, cause alterations in lipid metabolism [30].
Lipolysis is accelerated secondary to increased b2-adrener-
gic stimulation [31,32]. Elevated concentrations of
glucagon, TNF-a, IL-1, interferon-a and interferon-g
might also play a role in stimulating lipolysis [33–35].
Stimulation of the b2-receptors increases cyclic adenosine
monophosphate concentrations, which in turn stimulates
the activity of hormone-sensitive lipase [36]. The role of
the newly discovered b3-adrenergic receptor in human
lipolysis is still unclear [37]. The lipolytic response to b2-
stimulation is greater in lean than in obese persons [38].
There are regional variations in the lipolytic rate, with vis-
ceral fat cells having the greatest rate due to increased
activity of b2- and b3-receptors, and reduced activity of a2-
adrenergic receptors. Subcutaneous fat has reduced lipoly-
tic activity due to increased activity of insulin receptors
and a2-adrenoreceptors [39].
Rapid glycerol and free fatty acid turnover rates reflect the
accelerated lipolysis seen during stress [40]. The increase
in lipolysis also results in an increased systemic supply of
free fatty acids. The turnover rates are greater than those
expected from the increases in the plasma concentrations
of these substrates, however [40]. This indicates that there
is both increased re-esterification of free fatty acids to
triglycerides and increased lipolysis of triglycerides to free
fatty acids. This increased activity of the triglycerides–
fatty acid substrate cycle is thought to be one of the causes
of the hypermetabolism during stress. b-Adrenergic recep-
tor blockade with propranolol decreases lipid oxidation
and resting metabolic rates of burn patients [41]. Glucose
infusions further increase the lipolytic rate during abdomi-
nal surgery because they increase sympathetic nervous
system activity [31].
In the stressed state the relative caloric contribution of
fat oxidation to the resting energy expenditure is
increased and the contribution of glucose oxidation is
decreased [42]. The fatty acids released by lipolysis
undergo  b-oxidation, which in the stressed patient is the
predominant ATP-producing pathway. This situation is
reflected in observations made after oesophagectomy
[43] in which there was a gradual decrease in the contri-
bution of fat oxidation and increase in glucose oxidation
as patients convalesced.
Exogenous lipid administration
Intravenous exogenous lipid is most frequently adminis-
tered as an emulsion of long-chain triglycerides (LCT). In
the blood the lipid emulsion is converted to triglyceride-
rich particles, the size of which approximate those of
chylomicrons (diameter 200–500nm), and to phospho-
lipid-rich particles called liposomes produced from the
emulsifier [44]. The chylomicron-like particles are
hydrolyzed by lipoprotein lipase and release fatty acids.
The liposomes stimulate cholesterogenesis and accumu-
late in the blood as the long-lived abnormal lipoprotein-X.
The athrogenic potential of lipoprotein-X is under study
[45]. Patients with sepsis and multiple organ dysfunction
efficiently metabolize intravenous lipid emulsion, even
when chronic hepatic failure is present [46].
Exogenous lipid is needed to prevent essential free fatty
acid deficiency, so it is recommended that patients receiv-
ing TPN receive lipid emulsion infusion (500ml 10%
LCT emulsion) two to three times a week. It is also used
as an energy substrate, given that lipid oxidation is the
predominant energy-producing pathway. There has been
some debate as to whether exogenous lipids (LCT) are a
useful energy substrate. This debate has been occasioned
by observations that exogenous LCT failed to suppress
glucose oxidation in the critically ill. In normal postabsorp-
tive individuals the administration of LCT or
LCT/medium-chain triglycerides (MCT) emulsions
reduced glucose oxidation, but not tissue glucose uptake
[47,48]. Others, however, have not observed suppression
of glucose oxidation in normal persons when LCT emul-
sion was added to a glucose infusion [49]. Similarly, in crit-
ically ill patients the addition of LCT emulsion did not
modify glucose metabolism so that 45% of the adminis-
tered fat was stored [50]. Others observed that fat emul-
sions were well oxidized when administered to septic and
trauma patients, even when glucose was administered
[51]. Clarification is needed regarding the fate of adminis-
tered fat emulsions and their effects on the metabolism of
other substrates. Current practice is to consider lipid
emulsions as an energy substrate and to adminster them as
30–40% of total calories.
Concern has been expressed over the possible immuno-
suppressive effects of lipid emulsions. Ex-vivo studies
have demonstrated decreased neutrophil bacterial killing,
depression of monokine expression and other immunode-
pressant effects [52]. A recent study in trauma patients
[53] attributed an increased incidence of infections to lipid
emulsion administration. This has led to recommenda-
tions to limit fat calories to 30% of total calories [54].
Alternate fuels
There has been interest in substituting MCT for some of
the LCT. MCT do not require carnitine to enter the mito-
chondria and so may be advantageous in situations where
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are essentially an energy substrate; it is unclear whether
they can be stored. Less lipoprotein-X is produced when
emulsions containing both MCT and LCT are used. In an
attempt to reduce the toxicity of the MCT, structured
lipids have been developed. These are lipids with both
LCT and MCT bonded to the glycerol backbone (Fig. 2).
They are touted to have higher oxidation rates, faster
clearance rates and lower reticuloendothelial system accu-
mulation than MCT [55].
The soybean-derived fat emulsions traditionally used for
parenteral nutrition contain w6 polyunsaturated fatty acids,
specifically arachnodonic and linoleic acids. Arachnodonic
acid is the precursor for prostaglandins such as thrombox-
ane-A2 and prostaglandin-E1, which are associated with
platelet aggregation and inflammation. Alternately, fish
oils contain w3 fatty acids (eg eicosapentaenoic and
linolenic acids). These are precursors of another class of
prostaglandins that include thromboxane-A3 which have
less platelet-aggregating activity and cause less inflamma-
tion. The platelets from postoperative patients infused
with fish oil-enriched soybean oil lipid emulsions for 7
days after surgery aggregated less than those administered
only soybean oil lipid emulsion [56]. w3 Fatty acids also
decreased the ex-vivo production of IL-1, IL-6, IL-2 and
TNF by peripheral blood mononuclear cells [57]. Oral
eicosapentaenoic acid intake after surgery improved lym-
phocyte proliferation and natural killer cell activity [58].
There has been some interest in using w3 fatty acids in
adult respiratory distress syndrome to reduce pulmonary
microvascular permeability and alveolar macrophage
prostaglandin and leukotriene synthesis [59,60].
Protein metabolism
Pathophysiology
One of the hallmarks of the metabolic response to injury is
catabolism (negative nitrogen balance). There is acceler-
ated proteolysis of skeletal muscle, which provides some
of the substrate for increased hepatic gluconeogenesis.
Reducing the rate of hepatic gluconeogenesis with
somatostatin does not decrease the rate of peripheral
protein breakdown, demonstrating that the accelerated
rated of hepatic glucose production is not linked to the
elevated level of peripheral protein breakdown [1]. The
degree of nitrogen loss is proportional to the degree of
stress, and abates as the patient convalesces [61]. The
increased protein breakdown is thought to be modulated
only partly by the endocrine stress hormones, such as cor-
tisol [62]. Instead, other mediators such as the cytokines
TNF-a, IL-1, IL-6 and interferon-g are involved in medi-
ating catabolic activity. It is the balance between these
catabolic hormones and anabolic hormones such as insulin
and insulin-like growth factors that determine the degree
of catabolism. A number of metabolic pathways may be
responsible for skeletal muscle proteolysis, including the
lysosomal calcium-activated, ATP–ubiquitin-dependent
proteolytic pathway [63]. The liver also contributes to
catabolism through the increase in clearance of a-amino
nitrogen (urea). After surgery the rate of this conversion is
doubled [64]. Blockade of glucagon and cortisol secretions
with a combination of etomidate, somatostatin and tho-
racic epidural anaesthesia decreased this clearance, thus
indicating roles for glucagon and possibly cortisol and
afferent neural reflexes in this process [65,66].
There is conflicting data regarding skeletal muscle protein
synthetic activity during stress. Some studies indicate
reduced (eg 31% decrease 24h after open cholecystec-
tomy) skeletal muscle protein synthesis, whether saline or
TPN are infused [67,68]. Others claim that the net nega-
tive nitrogen balance is due to an accelerated rate of
protein breakdown that is in excess of an increased protein
synthetic rate [69]. Tissues with rapidly replicating cells,
such as enterocytes, immune cells and keratinocytes,
exhibit reduced protein synthesis. The derangement of
protein metabolism is profound. Provision of TPN after
open cholecystectomy does not prevent the decline in
muscle protein synthesis observed 24h after surgery [67].
During stress there is increased hepatic synthesis of the
‘acute phase’ proteins such as fibrinogen, complement,
immunoglobulins and C-reactive protein. Increase in these
proteins is thought to lead to increased ability to fight infec-
tion. Simultaneously, there is reduced synthesis of binding
proteins, such as albumin prealbumin, and transferrin.
Exogenous protein administration
Amino acids and protein are basic components of nutri-
tional support regimens. The aim of administering exoge-
nous protein or amino acid is to attenuate the breakdown
of endogenous proteins by providing an alternate source of
amino acids for gluconeogenesis and protein synthesis.
Unfortunately, in the stressed state exogenously adminis-
tered amino acids and protein are not well utilized and
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Figure 2
Various types triglycerides are used in nutritional support. They differ in
the types of fatty acids attached to the glycerol backbone. Structured
lipids are currently under investigation. LCFA, long chain fatty acid;
MCFA, medium chain fatty acid.
C-LCFA C-MCFA C-MCFA
C-LCFA C-MCFA C-LCFA
C-LCFA C-MCFA C-MCFA
Long-chain Medium-chain Structured
triglyceride triglyceride triglyceridenitrogen balance remains negative well into the convales-
cent stage. In the acutely stressed state proteolysis is rela-
tively unresponsive to the usual feedback mechanisms,
such as the administration of exogenous glucose, protein
or amino acids. In the catabolic state an intake of
1.2–1.5g/kg per day protein/amino acid is recommended
and higher amounts do not promote further nitrogen
retention. Instead the added protein/amino acid is metab-
olized to urea, so the blood urea nitrogen may rise. Situa-
tions associated with large external losses of protein, such
as extensive burns and large draining abscesses, make it
necessary to increase protein/amino acid intake.
One of the important consequences of glucose and carbohy-
drate administration is the stimulation of insulin secretion.
At lower doses insulin decreases protein breakdown by
inhibiting the major catabolic pathway, the ATP–ubiquitin
proteasome proteolytic pathway [70]. At higher doses it is
thought also to stimulate protein synthesis. Suppression of
insulin secretion during stress hormone infusion (cortisol,
glucagon, epinephrine) in normal individuals increased
whole-body nitrogen losses and the forearm efflux of amino
acids [71]. The administration of small doses of insulin to
burn patients increased skeletal muscle protein synthesis
[72] and improved wound matrix formation [73]. The provi-
sion of hypocaloric parenteral nutrition with high-dose
insulin improved nitrogen balance in postoperative cancer
patients [74]. The anabolic effects of insulin on protein
metabolism were not evident in enterally fed trauma
patients. Therefore, the route of nutrient intake may play a
role in the anabolic effects of insulin [75].
Alternate approaches
The inability of the usual intake of protein/amino acids to
attenuate nitrogen losses significantly has led investigators
to examine ways of either decreasing proteolysis or
increasing protein synthesis. An initial attempt was to
provide branched-chain amino acid enriched solutions.
This resulted in some improvement in nitrogen balance,
but no improvements in outcome. More recent attempts
have focused on administering anabolic substances to
reduce protein oxidation and improve protein synthesis.
During the flow phase of stress concentrations of growth
hormone are reduced and there is resistance to its actions
[76]. Because of its anabolic properties (mediated through
insulin-like growth factor-1) there has been much study of
growth hormone administration in catabolic patients. The
aim of administering growth hormone is to increase nitro-
gen retention and promote wound healing. Growth
hormone administration in critically ill patients receiving
nutritional support has been observed to reduce nitrogen
loss and improve phosphate retention. A disadvantage of
growth hormone is its diabetogenic and lipolytic proper-
ties. In the studies performed thus far with growth
hormone administration in the critically ill [77,78], no
definitive improvement in patient outcome was observed.
Insulin growth factors (IGFs) are a family of polypeptides
that regulate cell growth. Their secretion is stimulated by
growth hormone and their bioavailability is modified by
IGF binding proteins. IGF-1 and its binding protein, IGF
binding protein-3, are both reduced during stress [79].
Like growth hormone, IGF-1 stimulates protein synthesis
at lower doses, and at higher doses it also reduces proteol-
ysis [80]. The administration of IGF-1 for 3 days
decreased protein oxidation and, when administered along
with its binding protein, IGF binding protein-3, attenu-
ated catabolism in burn patients [79,81]. More study of
these substances is underway.
Renal replacement therapy
Continuous renal replacement therapies, especially contin-
uous veno–veno haemodiafiltration, have improved the
treatment of critically ill patients suffering from acute renal
failure. These therapies have facilitated the provision of
enteral and parenteral nutritional support by allowing
patients to receive a full complement of calories and amino
acids/protein. This is due to the ability of continuous thera-
pies to efficiently remove excess fluid, urea and elec-
trolytes. These therapies also cause loss of amino acids,
however (10–15g/day [26]). This loss is reported to be
unrelated to amino acid intake and related to plasma amino
acid concentration, volume of dialysate effluent and filter
efficiency [82]. The concentrations of most amino acids are
the same in the plasma and the dialysate [83]. Therefore,
the amino acid/protein content of the nutritional support
should be increased. With aggressive hemodiafiltration it
was possible to feed patients as much as 2.5g/kg per day
protein and achieve a positive nitrogen balance [84].
Route of administration
Pathophysiology
There has been increased emphasis on using the enteral
route for nutritional support occasioned by the desire to
maintain gut integrity and so lessen the translocation of
bacteria from the gut [85]. Lack of enteral intake, such as
occurs among postoperative and critically ill patients
receiving only parenteral nutrition, is associated with small
intestinal villus atrophy, decreased villus cell count and
reduced mucosal thickness, but not with changes in crypt
cell count [86]. Intestinal permeability, measured using
the urinary lactulose : mannitol ratio, is increased [86].
Also, crypt length is increased and mucosal surface pat-
terns change from finger-like to leaf-like microvilli [87].
These changes were reversed with enteral feeding [86,88].
Similar changes, along with activation of the lamina
propria mononuclear cells and enterocytes, were seen
during nutritional depletion [89–91]. Interestingly, there
was no evidence of mucosal atrophy among patients who
had received 10 days of preoperative parenteral nutrition
[92]. It is thought that these anatomic changes in and of
themselves do not lead to bacterial translocation, but that
further insult is needed. One such insult is ischaemia–
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from an episode of shock, which may also itself change gut
integrity [93]. Furthermore, in the stressed patient there is
the possibility that the constantly proliferating gut tissues
(epithelial and lymphoid cells) may have an inadequate
supply of nutrients, further compromising gut integrity [94].
These changes in gut integrity have led many to consider
whether after a systemic insult intestinal translocation of
bacteria occurs in critically ill humans. This concern is
based on studies of animal models that describe the
translocation of gut organisms across intestinal mucosa
with enhanced permeability. This bacterial translocation
leads to local activation of the gut’s immune inflammatory
system (Peyer’s patches and hepatic Kuppfer cells [95]).
The released cytokines and other mediators then exacer-
bate the already existing systemic inflammatory response
syndrome leading to multiple organ failure [96]. There is
no overwhelming evidence of translocation in humans
[97]. Intestinal serosal and mesenteric lymph nodes
showed evidence of bacteria in 10.3% of 269 general
surgery patients and in only 5% when those with inflam-
matory bowel disease and intestinal obstruction were
excluded. These observations led to the conclusions that
translocation can spontaneously occur in humans [98].
Indirect evidence comes from patients with intra-abdomi-
nal sepsis who showed reduced numbers of immunoglob-
ulin A and M plasma cells. It was speculated that the
reduced expression of these immunoglobulins might
favour bacterial adhesion to enterocytes [99].
Nutritional support
This ‘gut hypothesis of multiple organ failure’ has led to
the recommendation that enteral nutrition be started as
soon as possible after surgery or in nonsurgical patients
after admission to the intensive care unit. It is hoped that
enteral nutrition will preserve splanchnic flow and prevent
mucosal breakdown [100]. Further impetus to begin
enteral nutrition early has been lower stress hormone con-
centrations, lower infection rates, shorter hospital stays
and better survivals in some, but not all [101,102] studies
in which nutrition was started within 4–24h, and not more
than 24h after admission [103–105]. Other studies that
compared parenteral with enteral nutrition in pancreatitis,
postoperative states, burns and the critically ill have indi-
cated fewer infections and even shorter hospital stays,
although many of these studies contained only a small
number of patients.
A review of the literature by Lipman [106] revealed little
absolute evidence that enteral nutrition is better than par-
enteral nutrition, with the exception of lower cost and pos-
sible reduced septic morbidity in acute trauma patients
[1078]. It is intuitive, however, that the eventual goal in
critically ill patients is to feed them enterally as soon as
they are able to tolerate such intake. The problem is that
enteral feeding is fraught with both technical and physio-
logical challenges. These often result in inadequate caloric
intake, especially upon starting the nutrition. Therefore, it
may be necessary to supplement the enteral intake with
parenteral nutrition.
Alternate therapies
Glutamine has been the focus of much study because it
may be important in the maintenance of gut and immuno-
logical integrity during critical illness. It is the most abun-
dant free amino acid in the circulation and is a primary fuel
for rapidly dividing cells such as enterocytes and immuno-
cytes [108]. It is also involved in the inter-organ transport
of nitrogen. Evidence from animal studies has indicated
that glutamine may be an essential amino acid during criti-
cal illness and that parenteral and enteral glutamine-sup-
plemented nutrition may prevent bacterial translocation.
The data in humans are less compelling [109]. Glutamine
is rather insoluble and thus is difficult to administer. Some
success has been achieved infusing it as the L-amino acid,
glutamine-dipeptides or alanyl-glutamate. Initial reports
[110,111] indicate that in some catabolic patients gluta-
mine-containing nutrition may improve gut structure and
function, exert an anabolic effect and reduce morbidity,
hospital costs, infection rates and duration of hospital stay.
More studies are needed to ascertain whether glutamine
administration improves outcome [112].
Access for enteral nutrition is a problematic issue due to
the problems of securing a reliable route. Placement of the
tip of the tube into the jejunum is considered ideal so as to
avoid the often present gastric ileus and possibly prevent
aspiration. There has been some disagreement as to
whether it is mandatory to place the tube into the
jejunum. The ideal route is a jejunostomy catheter placed
during laparotomy, because feeding may begin within
hours of surgery. Complication rates are comparatively low
(1.5%) and most commonly involve catheter occlusion or
dislodgment. Very rarely bowel necrosis or intra-abdomi-
nal leaks may occur [113]. Alternatively, a nasoenteric
tube can be passed during surgery and manually manipu-
lated into the jejunum. In patients without surgical place-
ment, nasoenteric tubes may be placed. It is often difficult
to pass such tubes from the stomach into the jejunum.
Right lateral decubitus positioning and prokinetic drugs
may be tried, but often placement must be performed
under radiological or endoscopic guidance [114].
Pancreatitis
The traditional treatment of both acute pancreatitis and
acute exacerbation of chronic pancreatitis has been exclu-
sion of all oral intake and institution of nasogastric suction.
Nutritional support therefore has been delivered via the
parenteral route. Recently, there have been reports of suc-
cessful jejunal feedings with concomitant nasogastric
decompression among patients with moderate pancreatitis
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organ failure and/or pancreatic necrosis [115,116]). A small
randomized trial [117] found fewer total and septic com-
plications among patients who received parenteral nutri-
tion. Further study using larger randomized trials is
needed to confirm these findings.
The bottom line
The ultimate question is whether nutritional support
improves patient outcome, and, specifically, whether
nutritional support lowers mortality and mobility and
reduces intensive care unit and hospital durations of stay.
Unfortunately, there are no definitive large multicenter
studies that have examined this issue. There are a few
meta-analyses and large studies that have examined
selected aspects of nutritional support. A recent study
[118] claimed that starting enteral nutrition within 3 days
of intensive care unit admission reduces duration of
mechanical ventilation and improves outcome. A meta-
analysis using 26 studies [119] examined the relationship
between TPN and standard care (usual oral diet plus
intravenous dextrose), and complications and mortality
rates in surgical and critically ill patients. TPN had no
effect on mortality and only lowered complication rates in
malnourished patients. Studies published before 1988 had
significant treatment effect, whereas those published after
1989 did not. Complication rates, but not mortality, were
lower among patients who did not receive lipids. Another
meta-analysis of 11 randomized trials of both critically ill
and gastrointestinal malignancy patients [120] examined
the issue of immunonutrition (ie enteral nutrition supple-
mented with arginine, w3 fatty acids and purines). This
formulation is purported to improve immune function and
showed significant reductions in the risk of developing
infectious complications and in hospital stay. No effect on
mortality was observed.
Conclusion
There is a need to acquire more knowledge through large
multicenter studies of the cost–benefit and cost-effective-
ness of nutritional support in the critically ill, and specifi-
cally to clarify the issues of TPN versus enteral nutrition
and the use of specialized nutrients. Until such studies are
performed and the results analyzed, nutritional support
should continue to be viewed as an important adjunctive
therapy. It should be used in a manner that maximizes
positive effects and minimizes detrimental ones.
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